Waters launched a charge‑detection mass spectrometry platform aimed at accelerating analyses of protein complexes, nucleic acids and gene‑delivery vehicles, with a particular emphasis on rapid AAV capsid characterization (empty, partial, full and overfull) in under ten minutes per sample. The company said the technology will help biopharma and CDMOs improve analytics for gene‑therapy and complex biologic development. Waters positioned the system as shortening analytical cycles in process development and release testing for next‑generation biotherapeutics. For readers: charge‑detection MS provides mass and charge information on heterogeneous large assemblies, enabling faster, higher‑resolution quality control for particulate‑sensitive products like viral vectors and conjugates.